Related Experiment Video
Updated: Jul 6, 2026
Renal Ischaemia Reperfusion Injury: A Mouse Model of Injury and Regeneration
Published on: June 7, 2014
Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury
M Sandovici1, R H Henning, H van Goor
1Department of Clinical Pharmacology, Faculty of Medical Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. m.sandovici@med.umcg.nl
Abstract:
Ischemia-reperfusion injury is a leading cause of acute renal failure and a major determinant in the outcome of kidney transplantation. Here we explored systemic gene therapy with a modified adenovirus expressing Interleukin (IL)-13, a cytokine with strong anti-inflammatory and cytoprotective properties. When ischemia was induced we found that the IL-13 receptor is expressed in both the normal and experimental kidneys. Prior to the induction of ischemia, rats received adenovirus-IL-13, control adenovirus or saline. IL-13 plasma levels increased more than 50-fold in adenovirus-IL-13 treated animals, confirming successful IL-13 gene delivery. Histological analysis showed decreased tubular epithelial cell damage with adenovirus-IL-13 therapy, accompanied by reduced kidney injury molecule-1 expression. Interstitial infiltration by neutrophils and macrophages was reduced by half as was interstitial fibrosis and expression of alpha-smooth muscle actin. IL-13 treatment significantly diminished the expression of E-selectin, IL-8, MIP-2, TNF-alpha and MCP-1 mRNA. These results suggest that the use of systemic IL-13 gene therapy may be useful in reducing renal tubulointerstitial damage and inflammation caused by ischemia-reperfusion.
Insights
Systemic gene therapy using Interleukin (IL)-13 reduced kidney damage and inflammation following ischemia-reperfusion injury. This approach shows promise for preventing acute renal failure and improving kidney transplant outcomes.
Area of Science:
- Nephrology
- Immunology
- Gene Therapy
Background:
- Ischemia-reperfusion injury is a primary cause of acute kidney injury and impacts kidney transplant success.
- Interleukin (IL)-13 is a cytokine known for its anti-inflammatory and cytoprotective effects.
Purpose of the Study:
- To investigate the efficacy of systemic gene therapy with adenovirus-IL-13 in mitigating ischemia-reperfusion injury in a rat model.
- To evaluate the impact of IL-13 gene therapy on renal tubulointerstitial damage, inflammation, and fibrosis.
Main Methods:
- Rats were administered adenovirus-IL-13, a control adenovirus, or saline prior to inducing ischemia.
- IL-13 plasma levels were measured to confirm gene delivery.
- Histological analysis assessed tubular damage, inflammatory cell infiltration, fibrosis, and expression of specific injury markers and inflammatory mediators.
Main Results:
- Adenovirus-IL-13 treatment led to a significant increase in IL-13 plasma levels.
- Histological examination revealed reduced tubular epithelial cell damage and decreased expression of kidney injury molecule-1.
- Inflammatory cell infiltration (neutrophils, macrophages), interstitial fibrosis, alpha-smooth muscle actin expression, and key inflammatory markers (E-selectin, IL-8, MIP-2, TNF-alpha, MCP-1) were significantly diminished.
Conclusions:
- Systemic IL-13 gene therapy effectively reduces renal tubulointerstitial damage and inflammation associated with ischemia-reperfusion injury.
- This therapeutic strategy holds potential for managing acute renal failure and enhancing kidney transplantation outcomes.
Related Concept Videos
01:29Acute Kidney Injury II: Pathophysiology
01:22Acute Kidney Injury I: Introduction
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention